Considerations for Successful Upstream Process Development - Selection of the right cell line, culture medium, and bioreactor conditions is key to setting up the upstream portion of the biopharmaceuti


Considerations for Successful Upstream Process Development
Selection of the right cell line, culture medium, and bioreactor conditions is key to setting up the upstream portion of the biopharmaceutical manufacturing process.

BioPharm International
Volume 25, Issue 7, pp. 48-50

BioPharm: Can you discuss the concept of manufacturability as it applies to a biological product? When developing a cell-culture process, what parameters should a developer be considering to ensure manufacturability?

Ng: The end goal of cell culture process development is a robust manufacturing process that generates quality products through the cultivation of cells to meet the market demand. The keywords in that statement are 'quality products' and 'market demand,' and there are multiple ways to deliver the end goal. Nevertheless, considerations for manufacturability should be heavily assessed during process development. The concept of manufacturability will ensure that the process being developed can in fact be safely and appropriately applied in a large-scale manufacturing facility.

A developer should always keep the process simple and consider the operational limitations and equipment required or involved in large-scale manufacturing. Facility fit is a key aspect in manufacturability. A process should be developed with the final state in mind and the developer should also be prepared for the expected differences in large-scale manufacturing. Those differences may include osmolality, pCO2 level, some metabolite levels, shear level, and hydrodynamics across scales. Another factor to consider is the availability of GMP-grade raw materials for culture media additives. Any of these expected differences should be properly assessed, documented, and addressed.

BioPharm: What advice would you offer to someone who is starting out in cell culture process development?

Ng: The cell-culture process is a fairly complex process that includes several activities and development constraints from the business and regulatory sides, as well as timeline considerations. Consideration for process safety should always be the top priority. One piece of advice I have for a process developer is to know the end point and know the development system well. Among the end points are target yield, desired product quality attributes, timeline, business, or regulatory needs. The development system will include not only the upstream process development, but also downstream, analytical, as well as formulation development. The developer needs to use reasonable risk assessment tools that are scientifically based to guide the development process and decision making. Last but not least, a developer should consider the extended effect of the process as far forward as possible and as early as possible during development. Remember that each process is unique with its own requirements as well as constraints.

Robin Ng, PhD is a senior bioengineer in process development at Shire Pharmaceuticals in Lexington, MA.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here